What's breaking now, across thousands of outlets.
(RTTNews) - Shares of Iovance Biotherapeutics, Inc. (IOVA) are gaining about 33 percent on Tuesday morning after the company announced its decision to raise its full year 2026 total revenue guidance range to $410 to $420 million, driven by strong U.S. demand for Amtagvi and Prole
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
Boston-based eSecLending, founded in 2000, provides securities lending, auction and collateral management services to pension funds, insurers and asset managers worldwide.
Customer retention drives sustainable growth. Learn how to reduce churn, build customer loyalty, and turn existing customers into lifelong customers.
Key PointsNuScale won’t deploy its first SMRs until the early 2030s.
Indications that the smart ring’s shares were likely to price at the low end of the $40-to-$44 range delayed the plans, a person familiar with the matter said.
Markets expect the Fed to raise rates at both remaining 2026 meetings as inflation stays high, with investors watching October and December decisions closely.
Find insight on U.K. utilities, TotalEnergies, and more in the latest Market Talks covering Energy and Utilities.
